ASCO 2021: A Focus on Breast Cancer (eBook)
ASCO Breast Cancer Annual Meetingv1.indd
ASCO 2021 Breast Cancer
T-DXd Combinations in HER2-positive Metastatic Breast Cancer
The DESTINY-Breast07 trial will test trastuzumab deruxtecan (T-DXd) combinations in patients with HER2-positive advanced or metastatic breast cancer, as a phase 1b/2, open-label, multicenter, dose-finding and dose-expansion...
Preventing interstitial lung disease in patients on trastuzumab detruxtecan
Results from the phase 2 clinical trial DESTINY-Breast01 showed that the investigational human epidermal growth factor receptor 2 (HER2)-targeted antibody-drug conjugate [Fam-] trastuzumab deruxtecan (T-DXd) has durable...
T-DXd Response on Brain Mets HER2+ Breast Cancer
Results from the phase 2 clinical trial DESTINY-Breast01 showed that the investigational human epidermal growth factor receptor 2 (HER2)-targeted antibody-drug conjugate [Fam-] trastuzumab deruxtecan (T-DXd) has just as durable...
Novel Treatment Regimen in the Neoadjuvant Setting with Trastuzumab Deruxtecan
This ongoing trial was presented at the American Society of Clinical Oncology (ASCO) Annual...
Excellent prognosis for breast cancer patients with ultra-low-risk gene signature
Analysis of 1,000 patients in the MINDACT trial identifies patients with ultra-low risk for distant recurrence. These patients could be candidates for further de-escalation of treatment. Gene signatures have proven successful in...
Olaparib benefits early breast cancer patients with BRCA1/2 germline mutation
A first interim analysis of the OlympiA trial demonstrates significantly improved invasive disease-free survival in patients with high risk, HER2-negative, germline BRCA1/2-mutated primary breast cancer after 1 year of adjuvant...
Venetoclax does not benefit ER-positive, HER2-negative metastatic breast cancer
Addition of the BCL2 inhibitor venetoclax to endocrine therapy does not improve clinical benefit in patients with ER-positive, HER2-negative, locally advanced/metastatic breast cancer, according to the primary analysis of the...
OlympiA Findings Support Adjuvant Therapy with PARP Inhibitor for Early-stage High-risk Breast Cancer
Survival benefit seen in early-stage HER-2 negative breast cancer with BRCA1/2 mutations Adding 12...
Financial Toxicity in Women with Breast Cancer
Patients with breast cancer prioritized affordability or maintaining functional independence when making treatment decisions. Because of this variability, preference evaluation during treatment decision-making could optimize...
The Mutations That Cause Highest Risk for Breast Cancer
Germline DNA samples from African American women from 10 U.S. studies were tested for mutations in 20 established breast cancer predisposition genes using a QIAseq multiplex amplicon panel as part of the Cancer Risk Estimates...
